Literature DB >> 8278822

Determination of the stereoisomers of hydroxychloroquine and its major metabolites in plasma and urine following a single oral administration of racemic hydroxychloroquine.

J Iredale1, H Fieger, I W Wainer.   

Abstract

Plaquenil (hydroxychloroquine, HCQ; Sanofi Winthrop Pharmaceuticals, New York, NY) is a stereoisomeric drug administered as a racemic (50: 50) mixture of two isomeric forms--(+) and (-) HCQ. To correlate clinical efficiency accurately with dose, it is necessary to determine the fate of both isomers. This will allow for the optimization of clinical dosing. A method has been developed for the quantitation of (+) and (-) HCQ and its major metabolites, desethylhydroxychloroquine (DHCQ), desethylchloroquine (DCQ), and bisdesethylchloroquine (BDCQ), in plasma and in urine. Application of this method in a preliminary study in four human volunteers is reported. After a single oral dose of 200 mg of Plaquenil, the average enantiomeric ratio of (+) to (-) HCQ was approximately 1 over an 8-hour period. However, the average cumulative 48-hour excretion of HCQ, DHCQ, and DCQ showed stereoselective excretion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8278822     DOI: 10.1016/s0049-0172(10)80011-3

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  8 in total

Review 1.  Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine.

Authors:  Mariana Babayeva; Zvi Loewy
Journal:  Pharmgenomics Pers Med       Date:  2020-10-23

Review 2.  Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review.

Authors:  Anwar M Hashem; Badrah S Alghamdi; Abdullah A Algaissi; Fahad S Alshehri; Abdullah Bukhari; Mohamed A Alfaleh; Ziad A Memish
Journal:  Travel Med Infect Dis       Date:  2020-05-06       Impact factor: 6.211

Review 3.  Insights of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) pandemic: a current review.

Authors:  Jyoti Choudhary; Shrivardhan Dheeman; Vipin Sharma; Prashant Katiyar; Santosh Kumar Karn; Manoj Kumar Sarangi; Ankit Kumar Chauhan; Gaurav Verma; Nitin Baliyan
Journal:  Biol Proced Online       Date:  2021-02-01       Impact factor: 3.244

4.  Development of a Physiologically Based Pharmacokinetic Model for Hydroxychloroquine and Its Application in Dose Optimization in Specific COVID-19 Patients.

Authors:  Miao Zhang; Xueting Yao; Zhe Hou; Xuan Guo; Siqi Tu; Zihan Lei; Zhiheng Yu; Xuanlin Liu; Cheng Cui; Xijing Chen; Ning Shen; Chunli Song; Jie Qiao; Xiaoqiang Xiang; Haiyan Li; Dongyang Liu
Journal:  Front Pharmacol       Date:  2021-02-12       Impact factor: 5.810

Review 5.  Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic.

Authors:  Bogna Grygiel-Górniak
Journal:  Clin Rheumatol       Date:  2021-07-03       Impact factor: 3.650

Review 6.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.

Authors:  K D Rainsford; Ann L Parke; Matthew Clifford-Rashotte; W F Kean
Journal:  Inflammopharmacology       Date:  2015-08-06       Impact factor: 5.093

7.  Development and Validation of Reversed-Phase High Performance Liquid Chromatographic Method for Hydroxychloroquine Sulphate.

Authors:  A Singh; C L Singh; R Gupta; S Kumar; M Kumar
Journal:  Indian J Pharm Sci       Date:  2015 Sep-Oct       Impact factor: 0.975

Review 8.  Antimalarials - are they effective and safe in rheumatic diseases?

Authors:  Ewa Haładyj; Mariusz Sikora; Anna Felis-Giemza; Marzena Olesińska
Journal:  Reumatologia       Date:  2018-06-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.